Medicine and Health Sciences Commons^™

Pharmacological Restoration Of Pkd1: A Novel Strategy For Prostate Cancer Therapy, Mohammed Sikander, Shabnam Malik, A. Rodriguez, Aditya Ganju, Bilal B. Hafeez, Fathi T. Halaweish, Subhash C. Chauhan, Meena Jaggi

Research Colloquium

Background: Prostate cancer has poor prognosis owing to late diagnosis and ineffective multimodal clinical treatment. Extensive efforts are ongoing to establish methods that can resolve the expression of genes implicated in disease development and treatment. Previously, we reported that Protein Kinase D1 (PKD1), a serine threonine kinase, controls a number of tumor suppressor functions including cell aggregation, cell motility, cell proliferation, and cell invasion. Thus, PKD1 is considered as an emerging therapeutic target for prostate cancer treatment.

Objective: To investigate the restoration of PKD1 by a pharmacological modulator ormeloxifene, which showed well-defined PK/PD and safety profiles in humans.

Methods: Proliferation, …

Thymoquinone Inhibits Prostate Cancer Progression By Modulating Cytochrome P450 (Cyps), Santosh K. Singh, Rajesh Singh

Research Symposium

Background: Prostate cancer (PCa) incidence and mortality remain high in African American (AA) than Caucasian American (CA) men. Multiple factors contribute to this critical disease disparity, androgen receptors (AR), and differences among variants of the genes such as Cytochrome P450 (CYP) are involved in androgen biosynthesis and metabolism that may switch to gene regulation for prostate growth. However, inhibitors have been approved for CYP genes, the major pitfall, undesirable side effects, and quality of life in those patients. Therefore, targeting CYPs with a natural compound, Thymoquinone (TQ), a constituent of Nigella sativa (black seed), potentially safe and curative option for …

In Vitro Evaluation Of Phthalimide Derivatives Against Cancer Cell Lines, Crystel A. Sierra Rivera, Muhammad Kashif, Lenci Karina Vazquez Jimenez, Gildardo Rivera Sanchez, Alfredo Juarez Saldivar, Alma Delia Paz Gonzalez, Alejandro Zugasti Cruz

Research Symposium

Los cánceres de pulmón, próstata e hígado se encuentran entre los más prevalentes en los hombres. El cáncer de mama, de cuello uterino y de tiroides se encuentran entre los más prevalentes en mujeres (OMS, 2019). El tratamiento del cáncer generalmente incluye quimioterapia y radioterapia; sin embargo, los medicamentos contra el cáncer disponibles tienen una selectividad baja y causan efectos adversos graves, como nefrotoxicidad, neurotoxicidad y mielosupresión (Matsuo et al., 2010). Por tanto, el diseño y desarrollo de compuestos como nuevos agentes anticancerígenos frente a los tipos de cáncer de mayor incidencia son de vital importancia en el campo de …

Differential Gene Expression Between African American And Caucasian American Prostate Cancer, Daniel L. Shen, Gregory T. Maclennan, Sanjay Gupta

Research Symposium

Background: African-American (AA) men have higher incidence and mortality from prostate cancer compared to Caucasian-American (CA) men. Increasing evidence suggests that genetic and molecular alterations play important roles. We identified a 5 gene panel viz. p-Akt (Ser473), chemokine (C-X-C motif) receptor 4 (CXCR4), fatty acid synthase (FASN), interleukin-6 (IL-6) and matrix metallopeptidase 9 (MMP-9) highly expressed in prostate cancer and analyzed their expression in AA and CA cohorts.

Methods: IHC of p-Akt, CXCR4, FASN, IL-6 and MMP-9 were evaluated in RRP specimens (n=20) from each ethnic group exhibiting Gleason scores ranging from 6 through 9.

Results: Low to medium staining …

Characterization Of Prostate Cancer In Transgender Women, Simita Gaglani, Rajveer Purohit, Ashutosh Tewari, Dara Lundon, Natasha Kyprianou

Research Symposium

Background: The risk of developing prostate cancer (PC) in transgender women is unknown. Many patients are unaware that the prostate is not removed during male-to-female surgical transition. It is unclear what the exposure of estrogens and androgen blockers in these transgender patients has on the prostate. Our aim was to examine and characterize the different presentations of PC in published cases and augment this with an additional case series from one institute.

Methods: A retrospective review of prospectively maintained medical records was performed identifying features of PC diagnoses in transgender women. These included age, duration of feminizing hormone therapy, PSA …

A Seemingly Low Risk Patient Develops Urosepsis As A Complication Of Transrectal Prostate Biopsy: A Case Study, Nicole Peritz, Gabrielle Oquendo, Yuhyun Kang, Elijah Humphries, Joy Zarandy

Research Day

Background:

Prostate cancer (PCa) is the most common cancer in men, and the second most common cause of cancer deaths in the United States. Approximately 1 million Americans undergo prostate biopsies annually, with 97% undergoing the transrectal prostate biopsy (TRPB). While TRPB is reliable and relatively low risk, nearly 7% of patients develop infectious complications, with 3% requiring hospitalization due to sepsis. Risk factors for developing infection post-TRPB include antibiotic resistance, >10 biopsy cores, diabetes mellitus, indwelling catheter, and African-American ethnicity. Identifying risk factors, considering a transperineal biopsy approach, and utilizing pre-procedural practices like rectal sterilization, screening urinalysis, prophylactic antibiotics, …

Resveratrol Downregulates Kif15 In Prostate Cancer Cells, Kyla Geary, Dianzheng Zhang

Research Day

Kinesin family member 15 (KIF15) is best known as a stabilizer for bipolar spindle formation during cell division. By interacting with the actin cytoskeleton, KIF15 is also involved in cell proliferation, apoptosis, and differentiation, and therefore implicated in several types of malignancies including liver, pancreatic, and breast cancers. In castration-resistant prostate cancer cells, KIF15 protects AR/AR-V7 from degradation by binding the N-terminus of AR/AR-V7 and enhancing the recruitment of deubiquitinating enzyme ubiquitin-specific protease 14 (USP14). On the other hand, KIF15 is upregulated by AR transcriptionally. We have previously reported that resveratrol (RSV) downregulates ARV7 in prostate cancer cells by enhancing …

Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy And Stereotactic Body Radiotherapy For Localized Prostate Cancer, Sarthak Shah

GW Research Showcase 2021-2024

No abstract provided.

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy For Prostate Cancer, Sarthak Shah

GW Research Showcase 2021-2024

No abstract provided.

Effects Of Lycopene And The Mediterranean Diet On Prostate Cancer: A Critical Analysis Of The Data, Natalie Silk, Dianzheng Zhang

Research Day

Background: Prostate cancer (PCa) is one of the most widespread cancers diagnosed in men in the United States and is the second leading cause of cancer-related deaths worldwide. PCa will be a major cancer-related burden both socially and economically in the near future. It has been shown that dietary intake of natural anti-inflammatory agents are capable of inhibiting cancer progression, but due to the nature of dietary studies it is difficult to accurately conclude that diet is capable of impacting chronic diseases and mortality.This systematic review aims to collect and evaluate literature focused on prostate cancer progression and the natural …

Inhibiting Ror1 Expression In Androgen-Independent Prostate Cancer Reduces Aggressive Cancer Phenotypes By Modulation Of Akt-Gsk3Ꞵ Pathway, Vignesh Sivaganesh, Nazifa Promi, Salma Maher, Bela Peethambaran

Research Day

Prostate cancer is a disease that has a high prevalence and mortality amongst men. The severity of the cancer is stratified by risk, which is based on the Gleason grade, prostate-specific antigen (PSA) level, and clinical staging. Unlike breast cancer which can be classified into subtypes based on molecular heterogeneity, prostate cancer has no such classification and is treated with observation, prostatectomy, or radiation if local, and non-specific chemotherapy and androgen deprivation therapy (ADT) if metastatic. It is of the utmost importance to investigate molecular targets that can specifically eradicate prostate cancer while retaining the functions of normal tissue. Receptor …

Metastatic Adenocarcinoma Of The Prostate To The Brain Initially Diagnosed As Meningioma By Craniotomy: A Case Report, Julia T. Scali, Young Son, Paul Chialastri, Thomas Mueller

Rowan-Virtua Research Day

Prostate cancer is the second leading cause of cancer death in men after lung cancer. The most common site of prostate metastasis is bone (84%), lymph node (10.6%), liver (10.2%), and thorax (9.1%), with 18.4% to multiple metastatic sites [1]. Prostate metastasis to the brain is rare, with less than 1% documented cases from M.D. Anderson Cancer Center [2]. It is estimated that 1%-6% of prostate cancer metastasis is found in post mortem examination [3]. Parenchymal brain metastasis has a mean survival of 9.2 months after discovery of brain metastasis [4]. Acute neurological symptoms of metastatic prostate cancer are observed …

Referral Patterns, Procedures, And Outcomes Of A Large Community- Based Urology Group: A Retrospective Chart Review, Hassan A. Al Saleh, Gregory C. Mcmahon, Michael Douglas, Michael Console, Mihir Thaker, Gordon A. Brown

Rowan-Virtua Research Day

In 2012 The United States Preventive Services Task Force (USPSTF) recommended against prostate cancer (Pca) screening. The purpose of our study is to assess the effects of the USPSTF grade D recommendation for PSA based screening on new PCa diagnoses within a large-community based private practice setting. We completed a retrospective chart review of men with an elevated PSA seen in our clinic between May 2009–May 2015 who had undergone a prostate biopsy and were diagnosed with PCa. We observed that following the 2012 USPSTF recommendations, there was a significant increase in patients with clinically significant prostate cancer GG ≥ …